聚合内容 The Healthcare Sales & Marketing Network
Healthcare Sales & Marketing Network NewsFeed
更新时间: 11 分钟 57 秒 前

Nasrat Hakim Named Chairman of Board of Directors for Elite Pharmaceuticals

周三, 01/13/2016 - 14:32
Jerry Treppel Resigns NORTHVALE, N.J., Jan. 13, 2016 -- (Healthcare Sales & Marketing Network) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP) announced that Jerry Treppel has resigned as the Company’s Chairman and as a m...
Biopharmaceuticals, Personnel
Elite Pharmaceuticals

Nasrat Hakim Named Chairman of Board of Directors for Elite Pharmaceuticals

周三, 01/13/2016 - 14:32
Jerry Treppel Resigns NORTHVALE, N.J., Jan. 13, 2016 -- (Healthcare Sales & Marketing Network) -- Elite Pharmaceuticals, Inc. ("Elite" or the “Company") (ELTP) announced that Jerry Treppel has resigned as the Company’s Chairman and as a m...
Biopharmaceuticals, Personnel
Elite Pharmaceuticals

New Study Shows ICU Medical's SwabCap(R) Reduced Central Line-Associated Bloodstream Infections and Blood Culture Contamination, Corresponding To $3.2 Million Annual Savings

周三, 01/13/2016 - 14:27
In commenting on the peer-reviewed study by clinicians at New York City's Memorial Sloan Kettering Cancer Center, an editor for the New England Journal of Medicine noted that use of these devices could "markedly outweigh the added cost" in most i...
Devices
ICU Medical, SwabCap, disinfecting cap

New Study Shows ICU Medical's SwabCap(R) Reduced Central Line-Associated Bloodstream Infections and Blood Culture Contamination, Corresponding To $3.2 Million Annual Savings

周三, 01/13/2016 - 14:27
In commenting on the peer-reviewed study by clinicians at New York City's Memorial Sloan Kettering Cancer Center, an editor for the New England Journal of Medicine noted that use of these devices could "markedly outweigh the added cost" in most i...
Devices
ICU Medical, SwabCap, disinfecting cap

EnteroMedics Announces Closing of $11 Million Tranche from Previously-Announced Convertible Notes Offering

周三, 01/13/2016 - 14:20
ST. PAUL, Minn., Jan. 13, 2016 -- (Healthcare Sales & Marketing Network) -- EnteroMedics Inc. (ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announce...
Devices, Neurology, Venture Capital
EnteroMedics, vBloc Therapy, Maestro, neuromodulation

EnteroMedics Announces Closing of $11 Million Tranche from Previously-Announced Convertible Notes Offering

周三, 01/13/2016 - 14:20
ST. PAUL, Minn., Jan. 13, 2016 -- (Healthcare Sales & Marketing Network) -- EnteroMedics Inc. (ETRM), the developer of medical devices using neuroblocking technology to treat obesity, metabolic diseases and other gastrointestinal disorders, today announce...
Devices, Neurology, Venture Capital
EnteroMedics, vBloc Therapy, Maestro, neuromodulation

Epistem Appoints David Budd as Chief Executive Officer

周三, 01/13/2016 - 14:14
MANCHESTER, England, January 13, 2016 -- (Healthcare Sales & Marketing Network) -- Epistem Holdings Plc (EHP.L), the personalised medicine and biotechnology company, is pleased to announce the appointment of David Budd as Chief Executive Officer and as a ...
Diagnostics, Personalized Medicine, Personnel
Epistem Holdings, Genedrive

Epistem Appoints David Budd as Chief Executive Officer

周三, 01/13/2016 - 14:14
MANCHESTER, England, January 13, 2016 -- (Healthcare Sales & Marketing Network) -- Epistem Holdings Plc (EHP.L), the personalised medicine and biotechnology company, is pleased to announce the appointment of David Budd as Chief Executive Officer and as a ...
Diagnostics, Personalized Medicine, Personnel
Epistem Holdings, Genedrive

Galapagos and Gilead Cleared by U.S. Federal Trade Commission to Close Global Partnership on Filgotinib

周三, 01/13/2016 - 12:34
MECHELEN, Belgium & FOSTER CITY, Calif.--(Healthcare Sales & Marketing Network)--Galapagos NV (Euronext & NASDAQ:GLPG) and Gilead Sciences, Inc. (GILD) today announced that the U.S. Federal Trade Commission provided early termination of the waiting period ...
Biopharmaceuticals
Gilead Sciences, Galapagos, filgotinib, JAK1

Galapagos and Gilead Cleared by U.S. Federal Trade Commission to Close Global Partnership on Filgotinib

周三, 01/13/2016 - 12:34
MECHELEN, Belgium & FOSTER CITY, Calif.--(Healthcare Sales & Marketing Network)--Galapagos NV (Euronext & NASDAQ:GLPG) and Gilead Sciences, Inc. (GILD) today announced that the U.S. Federal Trade Commission provided early termination of the waiting period ...
Biopharmaceuticals
Gilead Sciences, Galapagos, filgotinib, JAK1

Contact us     New York    l    Miami    l    Sao Paulo     l    Mexico DF    l    London    l    Hong Kong